Aspirin ist nicht gleich Aspirin – Geschlechterunterschiede in der Pharmakologie

Frauen und Männer beschreiben nicht nur unterschiedliche Symptome, wenn sie krank sind. Sie sprechen auch unterschiedlich auf Medikamente an. Lesen Sie hier, wie diese Differenzen zwischen den Geschlechtern entstehen und weshalb es wichtig ist, sie in der Forschung zu berücksichtigen.

• Literatur

• 1 Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference?. Am Heart J 2004; 148: 27-33
• 2 Kim JS, Nafziger AN. Is it sex or is it gender?. Clin Pharmacol Ther 2000; 68: 1-3
• 3 Thürmann PA. Arzneimittelanwendung bei Frauen: ”off-label“?. Psychopharmakotherapie 2007; 14: 237-242
• 4 Haack S, Seeringer A, Thürmann PA et al. Sex-specific differences of psychotropic drugs: genes or gender?. Pharmacogeneomics 2009; 10: 1511-1526
• 5 Thürmann P, Janhsen K, Werner U et al. Sex-differences in the rate of adverse drug reactions associated with diuretics. Düsseldorf: German Medical Science GMS Publishing House; Im Internet: http://www.egms.de/en/meetings/gaa2008/08gaa11.shtml Stand 12.12.2011
• 6 Chen Z, Vaughn DA, Fanestil DD. Influence of gender on renal thiazide diuretic receptor density and response. J Am Soc Nephrol 1994; 5: 1112-1119
• 7 Brandoni A, Villar SR, Torres AM. Gender-related differences in the pharmacodynamics of furosemide in rats. Pharmacology 2004; 70: 107-112
• 8 Werner D, Werner U, Meybaum A et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 2008; 47: 323-332
• 9 Thürmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586-590
• 10 Wolbold R, Klein K, Burk O et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978-988
• 11 Cotreau MM, Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cyrochrome P450 3A substrates. Clin Pharmacokinet 2005; 44: 33-60
• 12 Luzier AB, Killian A, Wilton JH et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharm Ther 1999; 66: 594-601
• 13 Thürmann PA, Haack S, Werner U et al. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 2006; 80: 551-553
• 14 Niesters M, Dahan A, Kest B. Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. Pain 2011; 151: 61-68
• 15 Kornstein SG, Sloan DM, Thase ME. Gender-differences in depression and treatment response. Psychopharmacol Bull 2002; 36: 99-112
• 16 Martenyi F, Dossenbach M, Mraz K et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001; 11: 227-232
• 17 Ridker PM, Cook NR, Lee I-M et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304
• 18 Berger J, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006; 295: 306-313
• 19 Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411
• 20 Schmiedl S, Szymanski J, Rottenkolber M et al. Fingerhut – ein alter Hut? Eine Analyse stationärer Aufnahmen durch digitalisassoziierte unerwünschte Arzneimittelwirkungen. Med Klinik 2007; 102: 603-611
• 21 Martin R, Biswas PN, Freemantle SN et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505-511
• 22 Kubota K, Kubota N, Pearce GL et al. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in Prescription-Event Monitoring. Eur J Clin Pharmacol 1996; 49: 431-437
• 23 Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24: 575-585
• 24 Kahn SE, Zinman B, Lachin JM et al. Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care 2008; 31: 845-851
• 25 Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Endocrinol Metabol 2007; 92: 1305-1310
• 26 Tsang W, Alter DA, Wijeysundera HJ. The impact of cardiovascular disease prevalence on women's enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med ohne Seitenzahl 2011; [Epub ahead of print]
• 27 FDA. Evelyn B, Toigo T, Banks D et al. Women's participation in clinical trials and gender-related labeling. A review of new molecular entities approved 1995–1999 (24.08.2001). Im Internet: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ParticipatinginClinicalTrials/ucm197788.htm Stand 12.12.2011
• 28 Fleisch J, Fleisch MC, Thürmann PA. Women in early-phase clinical drug trials: Have things changed over the past 20 years?. Clin Pharmacol Ther 2005; 78: 445-452
• 29 Tenter U, Thürmann PA. References to sex-specific differences of drug effects in german SPCs for new entities from 1999 – 2004. Int J Clin Pharmacol Ther 2006; 44 (abstr.)